Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 29

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 29
---
 common shares and the January 2024 PIPE Warrants, the selling shareholders have
not had any material relationship with us within the past three years.

The table below lists the selling shareholders
and other information regarding the beneficial ownership of the common shares by each of the selling shareholders. The second column lists
the number of common shares beneficially owned by each selling shareholder, based on its ownership of the common shares and warrants,
as of November 25, 2025, assuming exercise of the Additional Warrant Shares underlying the January 2024 PIPE Warrants held by the selling
shareholders on that date, without regard to any limitations on exercises.

The third column lists the common shares being
offered by this prospectus by the selling shareholders.

In accordance with the terms of a registration
rights agreement with the selling shareholders, this prospectus generally covers the resale of the Additional Warrant Shares underlying
the January 2024 PIPE Warrants, determined as if the outstanding Additional Warrant Shares underlying the January 2024 PIPE Warrants were
exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each
as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the registration
rights agreement, without regard to any limitations on the exercise of the January 2024 PIPE Warrants. The fourth column assumes the sale
of all of the common shares offered by the selling shareholders pursuant to this prospectus.

Under the terms of the January 2024 PIPE Warrants,
a selling shareholder may not exercise the January 2024 PIPE Warrants, including the Additional Warrant Shares, to the extent such exercise
would cause such selling shareholder, together with its affiliates and attribution parties, to beneficially own a number of common shares
which would exceed 4.99% or 9.99%, as applicable, of our then outstanding common shares following such exercise, excluding for purposes
of such determination common shares issuable upon exercise of the January 2024 PIPE Warrants, including Additional Warrant Shares, that
have not been exercised. The number of common shares in the second column does not reflect this limitation. The selling shareholders may
sell all, some or none of their common shares in this offering. See “Plan of Distribution.”

| Name                                          
 of Selling Shareholder                        |     | Number        
 of            
 Common Shares 
 Owned         
 Prior to      
 Offering      |           |     |     | Maximum          
 Number of        
 Common